Burlington, MA 08 February 2019 – RedShift BioAnalytics (RedShiftBio) appoints new West Coast Sales and Support Manager to help satisfy demand for its award-winning protein characterization system. Subodh Nimkar joins the team to support sales on the West Coast of the United States. The AQS3pro was introduced and completed a very success beta program with major biotherapeutic development groups in 2018 and is now being incorporated into the analytical toolkit of companies developing life-saving biotherapeutics. Demand continues to grow as users discover the benefits of the technology to ‘See Change™ in the secondary structure of proteins.

Subodh has over 20 years of experience in protein characterization using various analytical technologies. His breadth of technical knowledge is perfect to educate on the benefits of Microfluidic Modulation Spectroscopy (MMS) versus less sensitive techniques like FTIR and CD-UV. Subodh joins RedShiftBio following a career in protein characterization at Applied Biosystems, protein QC at Pharmacia Biotech and cell surface protein marker characterization using Flow Cytometry at Streck.

The AQS3pro is designed for the development, formulation and manufacture of biotherapeutics. Enabling five key measurements—aggregation, quantitation, stability, similarity, structure—the AQS3pro ramps up the sensitivity, dynamic range and accuracy of IR spectroscopy over the concentration range of 0.1 to 200mg/mL. It features a powerful, integrated bioanalytics software that delivers automated, high sensitivity spectroscopic analysis.

“I decided to join RedShiftBio because of the exciting MMS technology that enables efficient and robust secondary structure characterization of biotherapeutics,’ commented Subodh. ‘This will lead to higher confidence in stability, efficacy and immunogenicity assessment during development. It will also make biosimilar product comparability/similarity studies far more efficient.’

If you would like to find out more about the AQS3pro then visit https://redshiftbio.com/mms.